Literature DB >> 2231651

Occurrence of the alpha thalassaemia-mental retardation syndrome (non-deletional type) in an Australian male.

M P Harvey1, A Kearney, A Smith, R J Trent.   

Abstract

The rare association of alpha thalassaemia and mental retardation has been described previously. Molecular studies of the alpha globin cluster in these cases have been heterogeneous, with some patients having large deletions while in others the alpha globin complex appears to be intact (non-deletional). The non-deletional cases form a distinct group whose features include severe mental retardation, haematological changes of haemoglobin H (Hb H) disease, developmental defects, and unusual patterns of inheritance. To date, five cases have been described with non-deletional alpha thalassaemia-mental retardation. We present here a further example of a young male of Northern European origin who appears to have the non-deletional form of the disease. Clinical features included severe mental retardation, Hb H disease, and developmental defects similar to those reported previously. DNA mapping, including pulsed field electrophoresis, showed no evidence of deletions within the alpha globin cluster. Karyotypic analysis indicated an increase in random breakage, which has been observed previously in one case of deletional alpha thalassaemia-mental retardation. Profuse Hb H bodies and Hb H on electrophoresis were consistent with Hb H disease. However, the latter was present at a relatively low level (1.6%) and, as well, the mean corpuscular volume (82.8 fl) and mean corpuscular haemoglobin (26.4 pg) were surprisingly high. Our findings are compared to other cases described with the non-deletional Hb H-mental retardation syndrome.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2231651      PMCID: PMC1017221          DOI: 10.1136/jmg.27.9.577

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  14 in total

Review 1.  A review of the molecular genetics of the human alpha-globin gene cluster.

Authors:  D R Higgs; M A Vickers; A O Wilkie; I M Pretorius; A P Jarman; D J Weatherall
Journal:  Blood       Date:  1989-04       Impact factor: 22.113

2.  Strategies for mapping and cloning macroregions of mammalian genomes.

Authors:  C L Smith; S K Lawrance; G A Gillespie; C R Cantor; S M Weissman; F S Collins
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

Review 3.  X-linked dominant control of F-cells in normal adult life: characterization of the Swiss type as hereditary persistence of fetal hemoglobin regulated dominantly by gene(s) on X chromosome.

Authors:  K Miyoshi; Y Kaneto; H Kawai; H Ohchi; S Niki; K Hasegawa; A Shirakami; T Yamano
Journal:  Blood       Date:  1988-12       Impact factor: 22.113

4.  Hemoglobin-H disease in association with multiple congenital abnormalities.

Authors:  D Borochovitz; S E Levin; S Krawitz; K Stevens; J Metz
Journal:  Clin Pediatr (Phila)       Date:  1970-07       Impact factor: 1.168

5.  Highly variable regions of DNA flank the human alpha globin genes.

Authors:  D R Higgs; S E Goodbourn; J S Wainscoat; J B Clegg; D J Weatherall
Journal:  Nucleic Acids Res       Date:  1981-09-11       Impact factor: 16.971

6.  Detection of breakpoints in submicroscopic chromosomal translocation, illustrating an important mechanism for genetic disease.

Authors:  J Lamb; A O Wilkie; P C Harris; V J Buckle; R H Lindenbaum; N J Barton; S T Reeders; D J Weatherall; D R Higgs
Journal:  Lancet       Date:  1989-10-07       Impact factor: 79.321

7.  Localisation of human alpha globin to 16p13.3----pter.

Authors:  V J Buckle; D R Higgs; A O Wilkie; M Super; D J Weatherall
Journal:  J Med Genet       Date:  1988-12       Impact factor: 6.318

8.  Post mortem findings in a patient with 46,XX,fra(2)(q13).

Authors:  A Smith; J Sullivan; W A Evans
Journal:  J Ment Defic Res       Date:  1989-02

9.  The major human erythroid DNA-binding protein (GF-1): primary sequence and localization of the gene to the X chromosome.

Authors:  L I Zon; S F Tsai; S Burgess; P Matsudaira; G A Bruns; S H Orkin
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

10.  Hemoglobin H disease and mental retardation: a new syndrome or a remarkable coincidence?

Authors:  D J Weatherall; D R Higgs; C Bunch; J M Old; D M Hunt; L Pressley; J B Clegg; N C Bethlenfalvay; S Sjolin; R D Koler; E Magenis; J L Francis; D Bebbington
Journal:  N Engl J Med       Date:  1981-09-10       Impact factor: 91.245

View more
  6 in total

1.  The non-deletion type of alpha thalassaemia/mental retardation: a recognisable dysmorphic syndrome with X linked inheritance.

Authors:  A O Wilkie; M E Pembrey; R J Gibbons; D R Higgs; M E Porteous; J Burn; R M Winter
Journal:  J Med Genet       Date:  1991-10       Impact factor: 6.318

2.  X linked alpha thalassaemia/mental retardation: spectrum of clinical features in three related males.

Authors:  A O Wilkie; R J Gibbons; D R Higgs; M E Pembrey
Journal:  J Med Genet       Date:  1991-11       Impact factor: 6.318

Review 3.  A newly defined X linked mental retardation syndrome associated with alpha thalassaemia.

Authors:  R J Gibbons; A O Wilkie; D J Weatherall; D R Higgs
Journal:  J Med Genet       Date:  1991-11       Impact factor: 6.318

4.  X linked mental retardation with non-deletional alpha thalassaemia (ATR-X): further delineation of the phenotype.

Authors:  R Ogle; M DeSouza; C Cunningham; B Kerr; D Sillence
Journal:  J Med Genet       Date:  1994-03       Impact factor: 6.318

5.  Alpha thalassaemia/mental retardation syndrome (non-deletional type): report of a family supporting X linked inheritance.

Authors:  T R Cole; A May; H E Hughes
Journal:  J Med Genet       Date:  1991-11       Impact factor: 6.318

6.  X-linked alpha-thalassemia/mental retardation (ATR-X) syndrome: localization to Xq12-q21.31 by X inactivation and linkage analysis.

Authors:  R J Gibbons; G K Suthers; A O Wilkie; V J Buckle; D R Higgs
Journal:  Am J Hum Genet       Date:  1992-11       Impact factor: 11.025

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.